Wikipedia -WSS

Wikipedia

author：leisure time 2025-09-06 04:40:46 - browse：737

Adam's take main illustration — Molly Ferguson/STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： UnitedHealth, Optum discontinue NaviHealth name

entertainment

WSS

Elevance PBM president out as customers face prescription chaos

STAT Summit: Meghan O’Rourke on making chronic illness visible

Sutter Health’s antitrust win overturned by appeals court

STAT Summit: Meghan O’Rourke on making chronic illness visible

How AI can help patients find reliable information about doctors

Is there really a nursing shortage in the U.S.?

knowledge

Wikipedia

entertainment

Apple is now the first public company to be valued at $3 trillion

STAT Summit: Meghan O’Rourke on making chronic illness visible

Cancer drug shortages should be causing more outrage

Health tech investors get more selective as pandemic boom fades

Drug repurposing or repositioning? The language matters

STAT Summit: Meghan O’Rourke on making chronic illness visible

State Dept. review finds Biden bears some blame for Afghanistan failures

Eli Lilly’s Zepbound improved liver scarring in mid

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

explore

Smaller biotechs seek to piggyback on weight loss drug boom

Health tech investors get more selective as pandemic boom fades

J&J lung cancer data amount to new salvo against AstraZeneca

STAT wants to know your pick for a great summer read or listen

STAT wants to know your pick for a great summer read or listen

STAT Summit: Ending the crisis of Black deaths in the U.S.

entertainment

knowledge

knowledge

entertainment